<DOC>
	<DOCNO>NCT00323024</DOCNO>
	<brief_summary>The purpose study determine safety maximum tolerate dose inhaled NX1011 treatment pulmonary arterial hypertension ( PAH ) .</brief_summary>
	<brief_title>Dose Determination Safety Activity Study Inhaled NX1011 Treat Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<criteria>Patient must either : meet PAH diagnostic criterion Screening ( base document history diagnosis outline American College Chest Physicians [ ACCP ] 2004 EvidenceBased Clinical Practices Guidelines ) 15 ; elevate pulmonary pressure suspect PAH diagnosis base clinical referral Screening RHC . Patient must PAH defined mean pulmonary artery pressure ( PAP ) &gt; 25 mmHg . Patient must symptoms pulmonary hypertension ( PH ) accord World Health Organization ( WHO ) Functional Classification Pulmonary Hypertension Class II IV . Patient must consent , able tolerate , adequate venous arterial access SwanGanz catheterization ( SGC ) arterial line . Clinically significant righttoleft intracardiac shunt base Doppler echocardiography bubble study . History pulmonary venoocclusive disease clinically significant aortic mitral stenosis . History sustain ventricular tachycardia ( VTS ) ventricular fibrillation ( VF ) cardiac arrest , presence atrial fibrillation . Active cardiac disease meeting follow criterion : Patient elevate pulmonary capillary wedge pressure ( PCWPs ) &gt; 25 mmHg . Patient history myocardial infarction coronary intervention within last 60 day . Patient history pacemaker , cardiac defibrillator , biventricular pacemaker insertion within 4 week Baseline . Patient withdrawn nitrate therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>Pulmonary Arterial Hypertension</keyword>
	<keyword>Pulmonary Hypertension</keyword>
	<keyword>Idiopathic PAH</keyword>
	<keyword>PH associate connective tissue disease ( CTD )</keyword>
	<keyword>PH associate interstitial lung disease ( ILD )</keyword>
	<keyword>PH associate congestive heart failure ( CHF )</keyword>
	<keyword>PH associate chronic obstructive pulmonary disease ( COPD )</keyword>
</DOC>